SBIR Phase I: MAUI Imaging 2D Probe for COVID-19

SBIR 第一阶段：针对 COVID-19 的 MAUI 成像 2D 探针

• 批准号: 2030301
• 负责人: Sateeshchandra Bajikar
• 金额: $ 25.49万
• 依托单位: MAUI IMAGING, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2030301&HistoricalAwards=false
• 关键词: SBIR; Phase; MAUI; Imaging; 2D

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an new way of imaging the entire chest and lungs, a critical capability in assisting physicians treat COVID-19 patients. Identification of COVID-19 patients with lung conditions enables accurate triage to appropriate care levels. Current imaging modalities are limited: CT scans are limited by logistics of patient flow, re-sterilization after use, cost, and radiation risk; and conventional ultrasound cannot penetrate the full depth of lung tissue. The proposed project will develop a portable ultrasound system for bedside low-cost, non-invasive, highly accurate imaging of the lung, delivered via remote streaming and control, for the complex logistics of COVID-19 patient care.This Small Business Innovation Research (SBIR) Phase I project will develop a portable ultrasound system for bedside non-invasive, highly accurate imaging of the lung parenchyma, mediastinum, and pleura. This project will develop core transducer components for integration into ultrasound probes, creating a 2-D imaging probe using 1-D transducer arrays. These 2-D arrays could ultimately be extended into a 3-D probe with full tomographic capabilities. The project will demonstrate the capability for lung imaging with sufficient quality to distinguish COVID-19 related issues without the need for accurate positioning, alignment, or registration.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力是一种对整个胸部和肺部进行成像的新方法，这是协助医生治疗COVID-19患者的关键能力。识别患有肺部疾病的COVID-19患者可以准确地将其分类到适当的护理水平。目前的成像方式是有限的：CT扫描受到患者流的物流、使用后的重新消毒、成本和辐射风险的限制;常规超声不能穿透肺组织的全部深度。 该项目将开发一种便携式超声系统，用于床边低成本、非侵入性、高精度的肺部成像，通过远程流媒体和控制进行传输，用于COVID-19患者护理的复杂物流。该小型企业创新研究（SBIR）第一阶段项目将开发一种便携式超声系统，用于床边非侵入性、高精度的肺实质、纵隔和胸膜成像。该项目将开发用于集成到超声探头中的核心换能器组件，使用1-D换能器阵列创建2-D成像探头。这些2-D阵列最终可以扩展成具有完整断层扫描能力的3-D探头。该项目将展示肺部成像的能力，其质量足以区分COVID-19相关问题，而无需精确定位，对齐或配准。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。